MT Newswires
Krystal Biotech Insider Sold Shares Worth $3,252,824, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
- Home
- KRYS
KRYS
Krystal Biotech Inc.
as of 03-09-2026 3:54pm EST
$259.18
+$5.05
+1.99%
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 7.8B | IPO Year: | 2017 |
| Target Price: | $297.60 | AVG Volume (30 days): | 260.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.84 | EPS Growth: | 128.00 |
| 52 Week Low/High: | $123.03 - $298.30 | Next Earning Date: | 05-18-2026 |
| Revenue: | $389,130,000 | Revenue Growth: | 33.94% |
| Revenue Growth (this year): | 40.88% | Revenue Growth (next year): | 35.16% |
| P/E Ratio: | 37.15 | Index: | N/A |
| Free Cash Flow: | 188.9M | FCF Growth: | +58.51% |
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
Romano Kathryn
Sell
Chief Accounting Officer
KRYS Mar 2, 2026
Avg Cost/Share
$267.60
Shares
750
Total Value
$200,700.00
Owned After
22,366
SEC Form 4
JANNEY DANIEL
Sell
Director
KRYS Feb 27, 2026
Avg Cost/Share
$275.81
Shares
11,803
Total Value
$3,252,824.35
Owned After
75,666
JANNEY DANIEL
Sell
Director
KRYS Feb 26, 2026
Avg Cost/Share
$275.80
Shares
7,741
Total Value
$2,133,679.46
Owned After
75,666
JANNEY DANIEL
Sell
Director
KRYS Feb 25, 2026
Avg Cost/Share
$275.00
Shares
700
Total Value
$192,500.00
Owned After
75,666
SEC Form 4
JANNEY DANIEL
Sell
Director
KRYS Feb 24, 2026
Avg Cost/Share
$267.26
Shares
51,720
Total Value
$13,823,203.64
Owned After
75,666
ROSSI DINO A
Sell
Director
KRYS Feb 19, 2026
Avg Cost/Share
$261.29
Shares
18,950
Total Value
$4,953,694.15
Owned After
78,691
Romano Kathryn
Sell
Chief Accounting Officer
KRYS Feb 9, 2026
Avg Cost/Share
$273.80
Shares
12,500
Total Value
$3,401,705.16
Owned After
22,366
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Romano Kathryn | KRYS | Chief Accounting Officer | Mar 2, 2026 | Sell | $267.60 | 750 | $200,700.00 | 22,366 | |
| JANNEY DANIEL | KRYS | Director | Feb 27, 2026 | Sell | $275.81 | 11,803 | $3,252,824.35 | 75,666 | |
| JANNEY DANIEL | KRYS | Director | Feb 26, 2026 | Sell | $275.80 | 7,741 | $2,133,679.46 | 75,666 | |
| JANNEY DANIEL | KRYS | Director | Feb 25, 2026 | Sell | $275.00 | 700 | $192,500.00 | 75,666 | |
| JANNEY DANIEL | KRYS | Director | Feb 24, 2026 | Sell | $267.26 | 51,720 | $13,823,203.64 | 75,666 | |
| ROSSI DINO A | KRYS | Director | Feb 19, 2026 | Sell | $261.29 | 18,950 | $4,953,694.15 | 78,691 | |
| Romano Kathryn | KRYS | Chief Accounting Officer | Feb 9, 2026 | Sell | $273.80 | 12,500 | $3,401,705.16 | 22,366 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 17, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 17, 2026 · 100% conf.
AI Prediction BUY
1D
+4.98%
$302.17
5D
+3.34%
$297.46
20D
+12.78%
$324.63
Price: $287.84 Prob +5D: 100% AUC: 1.000
0001711279-26-000018
krys-20260217FALSE000171127900017112792025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 17, 2026
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-38210 82-1080209 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code (412) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockKRYSNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 17, 2026, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter and year ending December 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.
The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated February 17, 2026
104Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 17, 2026
KRYSTAL BIOTECH, INC.
By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+4.98%
$302.17
5D
+3.34%
$297.46
20D
+12.78%
$324.63
Price: $287.84 Prob +5D: 100% AUC: 1.000
0001711279-26-000008
krys-20260111FALSE000171127900017112792026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-38210 82-1080209 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (412) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockKRYSNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 11, 2026, Krystal Biotech, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”) in advance of (i) the Company’s presentation on January 12, 2026 at the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”) and (ii) the Company’s participation in the Conference, including management’s discussions with investors and others. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2025. Specifically, the Press Release states that (i) the Company expects total net product revenues for VYJUVEK to be between $106 million and $107 million for the fourth quarter of 2025, and between $388 million and $389 million for the full year 2025, and (ii) the Company’s expectation with respect to its cash, cash equivalents and investments as of December 31, 2025, is approximately $955 million. In addition, the Press Release contains the Company’s rare disease strategic vision and 2026 corporate objectives, as well as preliminary 2026 combined non-GAAP R&D and SG&A expense guidance. A copy of the Press Release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
The preliminary financial information in this Item 2.02 is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the three months and year ended December 31, 2025. The audit of the Company’s financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The disclosure in Item 2.02 above is also being furnished under this Item 7.01.
The information contained in Items 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated January 11, 2026
104Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2026 KRYSTAL BIOTECH, INC.
By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001711279-25-000088
krys-20251103FALSE000171127900017112792025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-38210 82-1080209 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (412) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockKRYSNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 3, 2025, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.
The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated November 3, 2025
104Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 3, 2025
KRYSTAL BIOTECH, INC.
By: /s/ Krish S. Krishnan Name: Krish S. Krishnan Title: Chairman and Chief Executive Officer
Latest Krystal Biotech Inc. News
KRYS Breaking Stock News: Dive into KRYS Ticker-Specific Updates for Smart Investing
Compare KRYS vs Leading Stocks
See how KRYS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.